Peeling Back the Layers: This activity was supported by an independent educational grant from Pfizer A Best-Practice Approach to Managing Atopic Dermatitis Faculty 242** 204%*** Margaret Bobonich DNP, FNP-C, DCNP, FAANP Increase Program Details Peggy Vernon RN, MA, CPNP, FAANP **Diagnose** by Susan Tofte BSN, MS, FNP-C History & Goal To prepare the NP in clinical practice to recognize and assist patients to Exam appropriately manage Atopic Dermatitis Learning Objectives 32.8%** 42.6%** increase *Recognize Atopic Dermatitis and classify Target Audience NPs in Primary Care 850%*** Select Accreditation These activities were approved for 1.0 contact hours of continuing severity according to most recent guidelines. Classify treatment for Positive severity of AD education (CE), including 1.0 hour of pharmacology credit) by the American *Integrate patient-centered, best-practice 53.8%** severe AD Impact Association of Nurse Practitioners. approach to educate patient/parent on AD 920** disease management. 73% *** Live Event Venues to1,364*** *Select best individualized treatment(s) based patients/ Knowledge TNP 31st Annual Fall Conference **Memphis TN** on classification of severity. 3.8%** mo. Increase 29** increase **Tennessee Nurse Practitioner Association** 3/29/19 n=1* increase Advise to Reached Target Audience * Recommend resolve infant NMNPC 2019 Annual Conference Albuquerque NM home skin AD rash care **New Mexico Nurse Practitioner Counsel** 4/01/19 n=138 3,744 Total Learners Methods 93% NPs **2019 Annual Spring Conference** Northport ME increase 92% practice in family, adult or gerontology Utilizing infographics, Identify Maine Nurse Practitioner Association n=165 4/25/19 7.7 years in practice (average) case studies and patient photos, Hallmark ot 70% see patients with AD AD" Recognize learners were 2nd Annual Pharmacology Review Burnsville MN asked to integrate evidence-based The Minnesota APRN Coalition n=157 4/27/19 Self-reported practice changes 94% strategies to improve identification, increase**** 2019 AANP National Conference Indianapolis IN "AD became manageable management and treatment of 39%** 6/20/19 n=95 more quickly than with patients with atopic dermatitis **American Association of Nurse Practitioners** 84% Identify Classify previous attempts." Barriers to (AD). Severity a/t TNP 31st Annual Fall Conference **Austin TX** Treatment**** "Referred to dermatologist Guidelines n=77 **Texas Nurse Practitioners** 09/08/19 and started on biologic and **Delivery Formats** 67-81%** AD has tremendously *10-Live presentations AONP Tulsa OK improved." Confidence between March 2019 and **Association of Oklahoma Nurse Practitioners** n=92 10/03/19 "Better control of symptoms" Increase 93% October 2019 "Better patient education" increase**** Session recorded at AANP LANP New Orleans LA Integrate "AD tremendously improved National Conference June Select best Louisiana Association of Nurse Practitioners 10/04/19 n=115 evidencewith biologic" non-RXbased 2019 "More confidently diagnose" treatment NPAM 2019 Pharmacology Update treatment Columbia MD Launch of on-demand 98% increase plan "Consider biologics sooner" Nurse Practitioner Association of Maryland n=371 10/12/19 activity on AANP's CE **** Select "Incorporate systemic and Infographics medication Center January 25, 2020 – NPA's 35th Annual Conference **Verona NY** topical immunomodulators based on enhanced The Nurse Practitioner Association of New January 31, 2021 n=197 10/18/1 severity earlier" content 90%* **Live Sessions Total Learners 1,408 On-Demand Total Learners 1,236** Data source Combined

Data Analysis Utilizing Excel data brought into IBM Statistics Package for the Social Sciences for analysis, descriptive statistics paired analysis of pre/post results filtered to include only learners who treat patients with and an unpaired pre to follow-up analysis for the knowledge and case statistically significant differences pre to post and follow-up, McNemar and Chi-square test for 6 multiple choice knowledge/case questions, Wilcoxon and Mann-Whitney test for % correct out of 6 knowledge/case questions, and for each of 4 confidence rating scale questions. P ≤ 0.05 indicates a statistically significant difference, Effect Size (ES), to indicate the size of the change calculated, (Cohen's d): 0.20 = small, 0.50 = medium, 0.80 = large.